Dechra completed its acquisition of Gallant Pet Inc. on Nov. 17, 2026. Gallant is a U.S.-based animal health biotechnology company developing off-the-shelf mesenchymal stromal cell therapies for pets. The acquisition expands Dechra into regenerative medicine for veterinary care.
Deal terms
The companies finalized the transaction. Both parties agreed to keep the terms confidential. The announcement did not include a purchase price.
Company context
Dechra is a global leader in veterinary specialty care. Gallant is a U.S.-based animal health biotechnology company. It develops ready-to-use MSC therapies for pets.
What the deal adds
Gallant brings a regenerative medicine platform to Dechra. The therapies are designed to work with the body's natural biological processes. They target chronic and complex conditions in pets.
The first innovation from the Gallant pipeline is anticipated as early as 2027. The platform is designed to support multiple therapies across different conditions and species. Dechra plans to bring new treatment options to veterinarians and patients through its global reach and established relationships.